Covid-19 roundup: Re­gen­eron's mAB gets ex­pand­ed EUA; mR­NA drug­mak­ers spike price of vac­cines in EU sup­ply deal

The FDA has ex­pand­ed the au­tho­riza­tion for Re­gen­eron’s Covid-19 treat­ment Re­gen-Cov in an an­nounce­ment Fri­day.

The au­tho­riza­tion now cov­ers post-ex­po­sure pro­phy­lax­is for those ex­posed to an in­fect­ed per­son or who are at high risk of ex­po­sure “in an in­sti­tu­tion­al set­ting” like a nurs­ing home or a prison, and are not ful­ly vac­ci­nat­ed or ex­pect­ed to pro­vide a suf­fi­cient im­mune re­sponse.

Re­gen­eron ex­perts pre­dict that 3% of the US pop­u­la­tion may not be able to ful­ly re­spond to Covid-19 vac­ci­na­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.